Progressive cognitive and behavioral decline after seizure onset in previously normal children.
🔍
Diagnosis Trap
Normal MRI + absent dysmorphia = years of delay. High-cell karyotype (≥100 metaphases) essential to detect mosaicism.
Prevalence: ~1:500,000. Likely underestimated due to diagnostic difficulty. Males and females equally affected.
02 · Clinical Features
Seizure Semiology & Phenotype
Seizure types
Focal Impaired Awareness (nocturnal)Non-Convulsive Status EpilepticusTonic / AtonicIctal Hallucinations
Nocturnal FIAS
Sudden arousal from sleep
Sitting up, fear, agitation
Oroalimentary automatisms
Limb posturing
Terrifying hallucinations at onset
NCSE — Key Feature
Often daily, prolonged episodes
Confusional states, reduced responsiveness
Apathy, staring
Frequently misattributed to postictal or psychiatric
⚠ Clinical Pearl: The "confusional episodes" are often labeled behavioral/psychiatric for years. NCSE recognition requires prolonged EEG. This single recognition changes management.
03 · Neurophysiology
EEG Signature
Characteristic r(20) EEG Pattern — Schematic
Ictal Pattern
Long runs of rhythmic 4–6 Hz theta
Sharp waves / spikes superimposed
Frontotemporal predominance
Often bilateral / diffuse spread
NCSE on EEG
Continuous or near-continuous activity
Subtle behavioral correlate only
May persist hours daily
Easily missed on routine EEG
Key: Normal MRI + normal routine karyotype + "behavioral problems" + nocturnal events → request prolonged EEG and high-cell karyotype (≥100 metaphases).
04 · Diagnosis
Diagnostic Pathway
Stage 1 · Misdiagnosis Zone
Initial Presentation
Drug-resistant nocturnal seizures. Normal MRI. No dysmorphia. Behavioral changes labeled psychiatric. Standard karyotype (20–30 cells) may be NORMAL in mosaic cases.
Stage 2 · Suspicion
Clinical Pattern Recognition
Childhood-onset DRE + nocturnal FIAS + confusional episodes + normal MRI + cognitive decline → trigger r(20) workup.
Stage 3 · Confirmation
High-Cell Karyotyping
≥100 metaphases required. FISH or SNP array may add sensitivity. % mosaicism can loosely correlate with severity.
Stage 4 · Critical Step
Prolonged EEG / Video-EEG
Document NCSE. Quantify seizure burden. Essential for treatment planning. Ambulatory EEG acceptable for initial detection.
⚠ Do not: Proceed to invasive presurgical workup. r(20) is not a surgical candidate. Early recognition prevents futile SEEG workup.
05 · Treatment
Management Strategy
Drug
Evidence
Target
Notes
Valproic acid
Partial response
Broad spectrum
Most commonly reported; teratogenicity caution
Lamotrigine
Partial response
Sodium channel
Some cases respond, particularly FIAS component
Lacosamide
Partial response
Slow inactivation Na+
Reported benefit in small series
Clobazam
NCSE benefit
GABA-A (1,5 subtypes)
Particularly useful for NCSE; tolerance may develop
ACTH / Steroids
Case reports
Anti-inflammatory
Transient NCSE benefit; not standard of care
Cenobamate
No data
Na+ / GABA-A
No published data in r(20) — open research question
Multidisciplinary: Neuropsychological support · Special education · Behavioral/psychiatric management · Genetic counseling · Regular EEG monitoring (NCSE burden)
06 · Summary
Clinical Takeaways
🎯 The Recognition Pattern
Childhood-onset DRE + nocturnal FIAS + daily confusional episodes (NCSE) + normal MRI + no dysmorphia + cognitive decline → think r(20)
🔑 Don't Miss
Request ≥100 metaphase karyotype
NCSE on prolonged EEG
Benzodiazepine trial for NCSE
🚫 Avoid
Standard 20-cell karyotype only
Invasive presurgical workup
Attributing decline to "behavior" alone
Research gap @ Neurosphera: Cenobamate has no published data in r(20) syndrome. Systematic collection of outcomes in your cohort could yield publishable real-world evidence.
Neurosphera Epilepsy Center · Warsaw · Clinical Education Series · 2026